Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21416266 | 0.97 | NPC1 (0.40) | NPC1L3MBTL1MAPTLMNAHTT | |
| SCHEMBL23245124 | 0.93 | NPC1 (0.37) | NPC1L3MBTL1MAPTLMNAHTT | |
| SCHEMBL21410614 | 0.93 | NPC1 (0.37) | NPC1L3MBTL1MAPTLMNAHTT | |
| SCHEMBL25618130 | 0.90 | NPC1 (0.37) | NPC1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL25617799 | 0.88 | ALDH1A1 (0.40) | L3MBTL1MAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL25617795 | 0.88 | MAPT (0.44) | L3MBTL1MAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL25617606 | 0.87 | NPC1 (0.43) | NPC1L3MBTL1MAPTLMNAHTT | |
| SCHEMBL21410487 | 0.86 | NPC1 (0.37) | NPC1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL25619979 | 0.86 | L3MBTL1 (0.41) | NPC1L3MBTL1MAPTLMNAHTT | |
| SCHEMBL21410316 | 0.86 | NPC1 (0.37) | NPC1L3MBTL1MAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | ACHILLES MEDICAL LIMITED (NZ) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | AKR1C2, AKR1C1, AKR1B1 | NPC1 1212/4885L3MBTL1 4126/4885MAPT 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.